Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program

Monday, June 16, 2008 General News J E 4
SAN DIEGO, June 16 Victory Pharma, Inc., a specialtypharmaceutical company focused on pain and related areas of medicine, todayannounced the recent initiation of the first of two clinical studies forMGX006 antiemetic pivotal clinical program.

"Data from the Phase 2 studies confirming pivotal formulation selectionand end-of-phase 2 discussions with the FDA regarding the registration studydesigns provides confidence that MGX006 will move rapidly through pivotaldevelopment," explained Dr. Shawn Scranton, Vice President of ScientificOperations. "Victory is pleased with the results to date and is confident thatMGX006 will provide an important therapeutic alternative for patientssuffering from emesis of various etiologies," continued Dr. Scranton.

"MGX006 represents a key milestone for Victory," stated Matthew Heck,President and CEO. "This novel approach to antiemetic therapy is the company'sfirst internally developed pipeline product, demonstrating our commitment todeveloping solutions for unmet medical needs. We look forward to marketingMGX006 in the U.S. with our specialty sales force."

About MGX006

MGX006 utilizes a proprietary formulation applied to a previously approvedantiemetic agent. The formulation was created utilizing patented technologythrough a partnership and has properties that make MGX006 ideally suited forthe treatment of nausea and vomiting.

About Victory Pharma, Inc.

Victory Pharma, Inc. is a private San Diego based specialty pharmaceuticalcompany focused on acquiring, marketing and developing proprietary pain andrelated products. Victory markets its existing pain products through its fieldsales force headquartered in Cary, NC, and is currently developing severalproducts in pain and pain complementary markets. Further information regardingVictory is available at

SOURCE Victory Pharma, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Golimumab and Actemra Will Be Two of the Most Succ...
DermTech Adds Australian Thought Leader Dr. Scott ...